Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)
Status: | Completed |
---|---|
Conditions: | Liver Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - 85 |
Updated: | 10/2/2013 |
Start Date: | April 2009 |
End Date: | April 2012 |
Contact: | John L. Nosher, MD |
Email: | nosher@umdnj.edu |
Phone: | 732-235-7721 |
This study is being done to investigate the influence of giving radiation to the liver on
tumors involving the liver. Investigator is specifically looking at this effect on the
blood vessels within the tumor. This effect will be measured by studying substances in the
blood that the tumors produce and that cause blood vessels to grow. The effects seen on
these substances may help design other treatments to improve the results of the radiation
used to treat these tumors.
Subjects are invited to participate in this study that have undergone a procedure as their
standard of care. This procedure is known as Selective Internal Radiation Therapy (SIRT), a
procedure designed for the treatment of cancer in the liver. This includes cancer that has
started in the liver as well as cancer that has spread to the liver. The purpose of the
study is to collect blood samples to assess for "biological markers," or substances within
the blood that may promote cancer growth by causing new blood vessels to form. This study
will also use a new method of analyzing medical imaging (CT scan, PET scan) to try and
better understand how cancer in the liver forms new blood vessels. SIRT is standard therapy
and not part of this study. This study involves blood draws only.
Inclusion Criteria:
- Patient has been referred for SIRT as standard of care treatment for hepatocellular
carcinoma or colorectal metastases to the liver and qualify for treatment with SIRT
- Life expectancy of at least 3 months
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials